« Back
Home /
Tafasitamab

Tafasitamab

Item no.	HY-P9981-1ea
Manufacturer	MedChem Express
CASRN	1422527-84-1
Amount	1 ea
Quantity options	1 ea 1 mg 5 mg
Category	Antibodies Primary Antibodies
Type	Antibody
Specific against	other
Purity	99.0
Dry ice	Yes
Citations	[1]Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29.\|[2]Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res
Smiles	[Tafasitamab]
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	XmAb5574,MOR00208,Tafasitamab-cxix,MOR-208
Shipping Condition	Dry ice
Available
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Apoptosis
Shipping Temperature	Dry Ice
Storage Conditions	Store at -80°C for 2 years
Molecular Weight	(147.42 kDa)
Product Description	Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	H2O
Manufacturer - Pathway	Apoptosis
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P9981-1ea-safety-datasheet.pdf